TY - JOUR
T1 - CHLVPP chemotherapy with involved-field irradiation for hodgkin's disease
T2 - Favorable results with acceptable toxicity
AU - Vose, Julie M.
AU - Bierman, Philip J.
AU - Anderson, James R.
AU - Weisenburger, Dennis
AU - Moravec, Daniel F.
AU - Sorensen, Scot
AU - Hutchins, Mark
AU - Dowling, Monroe D.
AU - Howe, David
AU - Okerbloom, John
AU - Langdon, Robert M.
AU - Bascom, George K.
AU - Packard, William
AU - Pevnick, Warren
AU - Armitage, James O.
PY - 1991
Y1 - 1991
N2 - Patients with Hodgkin's disease who were previously untreated with chemotherapy received the chlorambucil, vinblastine, procarbazine, and prednisone (CHLVPP) regimen plus limited involved-field radiation therapy for treatment of Hodgkin's disease through the Nebraska Lymphoma Study Group. One hundred patients, 87 with newly diagnosed Hodgkin's disease and 13 who relapsed after receiving previous radiation therapy, were treated with this regimen between 1982 and 1989. Complete remissions (CRs) were obtained in 88 of 100 patients (88%), and there have been a total of eight relapses. The overall 3-year failure-free survival was 76%, with good-prognosis patients (ie, Karnofsky performance status ≥ 80) having a 3-year failure-free survival of 87%. Toxicity with this regimen was minimal, with neutropenic fevers reported in 13% of the patient population, moderate alopecia in 5%, and mild to moderate nausea and vomiting in 11 % of the patients. As primary-induction therapy for Hodgkin's disease, CHLVPP is an effective regimen with a high patient acceptance profile.
AB - Patients with Hodgkin's disease who were previously untreated with chemotherapy received the chlorambucil, vinblastine, procarbazine, and prednisone (CHLVPP) regimen plus limited involved-field radiation therapy for treatment of Hodgkin's disease through the Nebraska Lymphoma Study Group. One hundred patients, 87 with newly diagnosed Hodgkin's disease and 13 who relapsed after receiving previous radiation therapy, were treated with this regimen between 1982 and 1989. Complete remissions (CRs) were obtained in 88 of 100 patients (88%), and there have been a total of eight relapses. The overall 3-year failure-free survival was 76%, with good-prognosis patients (ie, Karnofsky performance status ≥ 80) having a 3-year failure-free survival of 87%. Toxicity with this regimen was minimal, with neutropenic fevers reported in 13% of the patient population, moderate alopecia in 5%, and mild to moderate nausea and vomiting in 11 % of the patients. As primary-induction therapy for Hodgkin's disease, CHLVPP is an effective regimen with a high patient acceptance profile.
UR - http://www.scopus.com/inward/record.url?scp=0025741823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025741823&partnerID=8YFLogxK
U2 - 10.1200/JCO.1991.9.8.1421
DO - 10.1200/JCO.1991.9.8.1421
M3 - Article
C2 - 2072145
AN - SCOPUS:0025741823
SN - 0732-183X
VL - 9
SP - 1421
EP - 1425
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 8
ER -